These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9651728)
21. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Dávila DF; Núñez TJ; Odreman R; de Dávila CA Int J Cardiol; 2005 Jun; 101(3):343-6. PubMed ID: 15907399 [TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine responses to acute myocardial infarction. Levine AB; Levine TB Henry Ford Hosp Med J; 1991; 39(3-4):151-4. PubMed ID: 1804818 [No Abstract] [Full Text] [Related]
23. Renal function as a predictor of prognosis in chronic heart failure. Hillege H; Van Gilst W; de Zeeuw D; van Veldhuisen DJ Heart Fail Monit; 2002; 2(3):78-84. PubMed ID: 12634888 [TBL] [Abstract][Full Text] [Related]
26. Methods to quantify sympathetic cardiovascular influences. Mancia G; Daffonchio A; Di Rienzo M; Ferrari AU; Grassi G Eur Heart J; 1998 Jun; 19 Suppl F():F7-13. PubMed ID: 9651729 [TBL] [Abstract][Full Text] [Related]
27. Pathophysiology of heart failure update: the role of neurohumoral activation in the progression of heart failure. Moser DK AACN Clin Issues; 1998 May; 9(2):157-71. PubMed ID: 9633270 [TBL] [Abstract][Full Text] [Related]
29. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. Teasell RW; Arnold JM; Krassioukov A; Delaney GA Arch Phys Med Rehabil; 2000 Apr; 81(4):506-16. PubMed ID: 10768544 [TBL] [Abstract][Full Text] [Related]
30. Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. Amadi A; Ponikowski P; Coats AJ J Cardiovasc Risk; 1995 Jun; 2(3):222-8. PubMed ID: 7584797 [TBL] [Abstract][Full Text] [Related]
31. Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure. Notarius CF; Floras JS Europace; 2001 Jan; 3(1):29-38. PubMed ID: 11271948 [TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine changes in heart failure and their clinical relevance. Parmley WW Clin Cardiol; 1995 Aug; 18(8):440-5. PubMed ID: 7586761 [TBL] [Abstract][Full Text] [Related]
33. Recognized molecular mechanisms of heart failure: approaches to treatment. Ceconi C; Cargnoni A; Curello S; Ferrari R Rev Port Cardiol; 1998 Oct; 17 Suppl 2():II79-91. PubMed ID: 9835784 [TBL] [Abstract][Full Text] [Related]
34. [Activation of the renin-angiotensin-aldosterone system in heart failure]. Volpe M; Tocci G; Pagannone E Ital Heart J; 2005 May; 6 Suppl 1():16S-23S. PubMed ID: 15945296 [TBL] [Abstract][Full Text] [Related]
35. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model. Nap A; Belterman CN; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):220-7. PubMed ID: 14689369 [TBL] [Abstract][Full Text] [Related]
36. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. Mancia G; Dell'Oro R; Quarti-Trevano F; Scopelliti F; Grassi G J Hypertens Suppl; 2006 Mar; 24(1):S51-6. PubMed ID: 16601574 [TBL] [Abstract][Full Text] [Related]
37. Sympathetic activation in cardiovascular and renal disease. Grassi G; Arenare F; Pieruzzi F; Brambilla G; Mancia G J Nephrol; 2009; 22(2):190-5. PubMed ID: 19384835 [TBL] [Abstract][Full Text] [Related]